Dual specificity protein phosphatases: Therapeutic targets for cancer and Alzheimer's disease

被引:78
作者
Ducruet, AP [1 ]
Vogt, A
Wipf, P
Lazo, JS
机构
[1] Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Inst Canc, Combinatorial Chem Ctr, Pittsburgh, PA 15261 USA
[3] Univ Pittsburgh, Inst Canc, Fiske Drug Discovery Lab, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Inst Canc, Dept Chem, Pittsburgh, PA 15261 USA
关键词
Cdc25; Cdk; MKP; MAPK; drug discovery;
D O I
10.1146/annurev.pharmtox.45.120403.100040
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The complete sequencing of the human genome is generating many novel targets for drug discovery. Understanding the pathophysiological roles of these putative targets and assessing their suitability for therapeutic intervention has become the major hurdle for drug discovery efforts. The dual-specificity phosphatases (DSPases), which dephosphorylate serine, threonine, and tyrosine residues in the same protein substrate, have important roles in multiple signaling pathways and appear to be deregulated in cancer and Alzheimer's disease. We examine the potential of DSPases as new molecular therapeutic targets for the treatment of human disease.
引用
收藏
页码:725 / 750
页数:26
相关论文
共 156 条
  • [21] Mammalian MAP kinase signalling cascades
    Chang, LF
    Karin, M
    [J]. NATURE, 2001, 410 (6824) : 37 - 40
  • [22] CHARLES CH, 1992, ONCOGENE, V7, P187
  • [23] THE GROWTH FACTOR-INDUCIBLE IMMEDIATE-EARLY GENE 3CH134 ENCODES A PROTEIN-TYROSINE-PHOSPHATASE
    CHARLES, CH
    SUN, H
    LAU, LF
    TONKS, NK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) : 5292 - 5296
  • [24] Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway
    Chen, F
    Zhang, Z
    Bower, J
    Lu, YJ
    Leonard, SS
    Ding, M
    Castranova, V
    Piwnica-Worms, H
    Shi, XL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (04) : 1990 - 1995
  • [25] Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase
    Chen, MS
    Hurov, J
    White, LS
    Woodford-Thomas, T
    Piwnica-WormS, H
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (12) : 3853 - 3861
  • [26] CONTOUR MOG, 2002, Patent No. 2003055868
  • [27] Issues and progress with protein kinase inhibitors for cancer treatment
    Dancey, J
    Sausville, EA
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) : 296 - 313
  • [28] Regulation of CDC25B phosphatases subcellular localization
    Davezac, N
    Baldin, V
    Gabrielli, B
    Forrest, A
    Theis-Febvre, N
    Yashida, M
    Ducommun, B
    [J]. ONCOGENE, 2000, 19 (18) : 2179 - 2185
  • [29] Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma
    Denkert, C
    Schmitt, WD
    Berger, S
    Reles, A
    Pest, S
    Siegert, A
    Lichtenegger, W
    Dietel, M
    Hauptmann, S
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (05) : 507 - 513
  • [30] Form and function in protein dephosphorylation
    Denu, JM
    Stuckey, JA
    Saper, MA
    Dixon, JE
    [J]. CELL, 1996, 87 (03) : 361 - 364